

## Section A. Privacy and consent

### 1. Privacy Information

Your personal information is protected by law, including the Privacy Act 1988 (Privacy Act) and the Australian Privacy Principles (APPs), and is being collected by Bastion Insights on behalf of the Department of Health and Aged Care, via Qualtrics, for the purposes of conducting a consultation process in relation to the HTA Review. Please download and read the [Privacy Notice](#) to find out how we manage the personal information we collect about you through the Consultation for the HTA Review.

Bastion Insights and the Department will collect your personal information at the time that you provide a submission.

To protect privacy, do not include identifying personal or sensitive information about another individual (third party).

### 2. How your input will be used

- Your submission and details you provide including identifying information about you or your organisation will be made available in full to the HTA Review Reference Committee and will be summarised and analysed for review.
- Your submission and identifying information about you or your organisation will be made available to Bastion Insights who have been commissioned by the Department to conduct analysis of the submissions.
- Your submission and details you provide will be summarised and analysed for reporting on the HTA Review Consultation which may be published on the Department website.
- Your submission and identifying information about you or your organisation may be published on the Department of Health and Aged Care Website, the Consultation Hub, or in related documents unless you request that they are not published.
- **Your personal contact details will not be published.**

### 3. Acknowledgement

I understand that my personal information will be used in accordance with the 'How will your input be used' and 'Privacy information' sections above.

- Yes (Required)
- Please withdraw my participation. (This will end the submission)

## Section A Privacy and consent contd.


The Department may, at its discretion, publish part or all of the information provided in your submission on the Department's website or in related documents. If information from your submission is published, the Department may identify you and/or your organisation as the author of the submission. All personal contact details will be removed prior to publishing.

- Yes, I consent to my identified submission being published
- Please publish my submission anonymously (personal and organisational names will be removed and the submission will be marked as 'Name withheld') (Note: if you select this option and your submission contains identifying information, your submission may not be published).
- No, do not publish my submission on the Department of Health and Aged Care website and/or the Consultation Hub

*Note, in line with the 'How will your input be used' and 'Privacy information' sections, all submissions will be made available to the HTA Review Reference Committee and considered in the consultation analysis and reporting, however, it is not guaranteed that stakeholder submissions will be published verbatim or in full on the Department of Health and Aged Care website or on the Consultation Hub.*

## Human

Please confirm you are human



## Section B: Expression of Interest

### How can I provide feedback?

You can have your say by participating in **one or more of the following options**:

- completing an online submission.

***Note: You will be given the opportunity to select the topics you wish to input on as part of your submission, and additional feedback can be uploaded at the end of the submission as a common file format (DOC / PDF)***

- attending an in-person workshop in Sydney Monday Friday 19th February 2024 (pending interest and stakeholder availability)
- participating in an online workshop via Microsoft Teams on either Tuesday 13<sup>th</sup>, Thursday 15<sup>th</sup> or Friday 16<sup>th</sup> February 2024 (pending interest and stakeholder availability)

The below details are required to identify you and allow us to contact you about the consultation. After completing the following section, you will be asked how you would wish to participate.

What is your full name?

First name *(Required)*

Last name *(Required)*

What is your email address? *(Required)*

What is your mobile phone number (or best contact number, including area code)?

*This is optional, and will only be used for the purposes of contacting you in the case of exceptional circumstances affecting the forums taking place.*

What is the name of your organisation?

- My organisation is called:
- Not Applicable

Please select the type of individual(s) or organisation(s) you represent. *Please select all that apply.*

- Patient or consumer (or representative organisation)
- Clinician (or representative organisation)
- Pharmaceutical / Medical technology company
- University or research sector
- Consulting
- Industry association / Peak body
- State / Territory government
- Federal government
- Other [please specify]

Are you making feedback on behalf of...?

- Yourself
- Your organisation

Note: If the submission is made on behalf of an organisation any reference made to the author of the submission will refer to the organisation rather than an individual.

## Section C: Declaration of Interests

### Declaration of Interests:

The purpose of this declaration is to discover any financial or professional interest on the part of a person, or on the part of their immediate family, who is providing input to the Health Technology Assessment Policy and Methods Review.

Such interests may affect, or have the appearance of affecting, a person's view on the merits of certain HTA policies or methods. The existence of such interests may be a 'conflict of interest'. A conflict of interest is declared so that information provided can be assessed fairly and in a transparent manner. **The declarations are confidential and do not prevent anyone from providing feedback.**

A financial interest may include, but is not limited to, any of the following involvement with companies or other organisations engaged in the development, manufacture, marketing or distribution of health technologies:

1. Current shareholdings
2. Board memberships or other offices
3. Paid employment or contracting work
4. Grants
5. Hospitality (including conferences, travel).

A professional interest may include, but is not limited to, involvement in any of the following:

1. Development, manufacture or marketing and distribution of vaccines, drugs and medicinal preparations
2. Making a public statement about certain HTA policies or methods or the outcomes of HTA processes.

Please include any declarations you wish to make.

No conflicts

Financial conflict/s (please specify)

Professional conflict/s (please specify)

## Section D. Submission preference

How would you like to provide feedback? *You may select just one or both.*

Complete an online submission

Attend a workshop (specify on the next page whether this would be in-person or online, pending stakeholder interest and availability)

*The Department understands written submissions may take longer to complete than the cut-off date for workshop registration (9th February 2024).*

*Therefore, the Department are **monitoring expressions of interest in workshop participation daily, including among in-progress submissions.***

*To all those who express interest in attending one of the workshop dates before the cut-off, a member of the Department will get in contact via the contact details you have provided to share details of the event and confirm your attendance.*

*The online workshops will run from **10am-1pm AEDT***

*The in-person workshop will run from **9:30am-3:30pm AEDT***

*Stakeholders have the option to attend multiple workshops*

Please indicate your availability on the following dates...

- 13 February 2024 - online workshop
- 15 February 2024 - online workshop
- 16 February 2024 - online workshop
- 19 February 2024 - in-person workshop (Sydney)
- None of these

And please indicate which is your preferred date ?

- I have no preference between these dates
- » 13 February 2024 - online workshop
- » 15 February 2024 - online workshop
- » 16 February 2024 - online workshop
- » 19 February 2024 - in-person workshop (Sydney)
- » None of these

## **Section E. Workshop Can Attend**

Thank you for expressing your interest in participating in a workshop, a member of the Department will get in contact via the contact details you have provided to share details of the event and confirm your attendance.

Select the next arrow to submit your expression of interest. You will then either be taken to the online submission if you opted to do so, or otherwise, redirected back to the HTA Review Options Paper landing page, and can then close your browser.

## **Section E. Workshop Can't Attend**

Thank you for expressing your interest in participating in a workshop. We're sorry that you are not available on any of the available workshop dates.

You can still complete an online submission. Should you so wish to, use the back arrow to return to this option (if not already selected), otherwise you will be redirected to the HTA Review Options Paper landing page, and can then close your browser.

## **Section F. Online submission – Selection of topics**

As mentioned, the Reference Committee for the HTA Review has received extensive inputs in relation to Health Technology Assessment (HTA) systems in Australia and overseas – how they are performing, and how well they are serving the needs of Australians. From this initial consultation, an Options Paper has been produced presenting options for reform being considered by the Reference Committee to improve HTA policies and methods and funding and approval pathways.

The full Options Paper can be accessed below:

- *Office Word 2007 XML document [here](#)*

The paper is divided into the following chapters:

1. Transparency, communication, and stakeholder involvement in HTA
2. Health technology funding and assessment pathways
3. Methods for HTA for Australian government subsidy (technical methods)
4. Health technology funding and purchasing approaches and managing uncertainty
5. Futureproofing Australia's systems and processes

Each chapter is broken down into several different topics or subjects which include details relating to:

- the current state in Australia and other jurisdictions (where applicable)
- what was heard from stakeholders
- identification or understanding of the issues (where these are formed), and
- potential options for reform.



Please select which chapter/s you would like to provide feedback on. You may provide feedback on as many or few chapters as you wish.

- 1. Transparency, communication, and stakeholder involvement in HTA
- 2. Health technology funding and assessment pathways
- 3. Methods for HTA for Australian government subsidy (technical methods)
- 4. Health technology funding and purchasing approaches and managing uncertainty
- 5. Futureproofing Australia's systems and processes

*To help you complete your submission we recommend you read each topic of the report and complete the respective section of the submission, before moving to the next topic.*

*For ease of completion the topics referenced in the online submission align to the labelling throughout the report.*

*Until the survey is submitted you can navigate forwards and backwards and may return to each page at any time. However, only submitted surveys will be read so please ensure you submit your survey promptly before the consultation period closes.*

*You may close and save the survey to complete at a later date before the consultation period closes.*

*Now please select the topics within the chapter(s) you would like to provide feedback on...*

## 1. Transparency, communication and stakeholder involvement in HTA

- 1.1. Transparency and communication of HTA pathways, processes and decisions
- 1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA
- 1.3. First Nations people involvement and consideration in HTA
- 1.4. State and territory government collaboration in HTA

## 2. Health technology funding and assessment pathways

- 2.1. Streamlining and aligning HTA pathways and advisory committees
- 2.2. Proportionate appraisal pathways

## 3. Methods for HTA for Australian government subsidy (technical methods)

- 3.1. Determination of the Population, Intervention, Comparator, Outcome
- 3.2. Clinical Evaluation Methods
- 3.3. Economic evaluation

## 4. Health Technology funding and purchasing mechanisms and decisions

- 4.1. Approaches to funding or purchasing new health technologies
- 4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR)
- 4.3. Understanding the performance of health technologies in practice

## 5. Futureproofing our systems and processes

- 5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS
- 5.2. Establishment of horizon scanning programs to address specific informational needs within HTA and the health system
- 5.3. Consideration of environmental impacts in the HTA
- 5.4. Mechanisms for continuous review and improvement
- 5.5. Capacity and capability of the HTA system
- 5.6. Strengthen international partnerships and work-sharing

### 1.1. Transparency and communication of HTA pathways, processes and decisions

Taking all Options within this section: **1.1. Transparency, communication and stakeholder involvement in HTA** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Publish plain language summaries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Improvements to the HTA webpage including development of a dashboard	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Publish plain language summaries

--

Improvements to the HTA webpage including development of a dashboard

--

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

--

## 1.2. Transparency and communication of HTA pathways, processes and decisions

Taking all Options within this section: **1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Develop an engagement framework	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Strengthen consumer evidence	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Develop an engagement framework

Strengthen consumer evidence

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### 1.3. First Nations people involvement and consideration in HTA

Taking all Options within this section: **1.3. First Nations people involvement and consideration in HTA** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
First Nations peoples partnership in decision making	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Dedicated resource for HTA submissions and education	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

First Nations peoples partnership in decision making

Dedicated resource for HTA submissions and education

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

#### **1.4. Transparency and communication of HTA pathways, processes and decisions**

Taking all Options within this section: **1.4. State and territory government collaboration in HTA** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Completely address the issue(s)



- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Development of central standardised data sharing system for utilisation and outcome data	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Increase opportunities for consultation and work sharing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Health technologies that are jointly funded by the Commonwealth and state and territory governments (such as high cost, Highly Specialised Therapies (HSTs) delivered to public hospital inpatients)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Development of central standardised data sharing system for utilisation and outcome data

Increase opportunities for consultation and work sharing

Health technologies that are jointly funded by the Commonwealth and state and territory governments (such as high cost, Highly Specialised Therapies (HSTs) delivered to public hospital inpatients)

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

## 2.1. Streamlining and aligning HTA pathways and advisory committees

Taking all Options within this section: **2.1. Streamlining and aligning HTA pathways and advisory committees** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Vaccine pathway	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Expanding role of PBAC	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Unified HTA pathway for all health technologies with Commonwealth funding	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))

Vaccine pathway

Expanding role of PBAC

Unified HTA pathway for all health technologies with Commonwealth funding

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

## 2.2. Proportionate appraisal pathways

Taking all Options within this section: **2.2. Proportionate appraisal pathways** into account

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answers above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Triaging submissions	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Streamlined pathway for cost-minimisation submissions (therapies not claiming a significant improvement in health outcomes or reduction in toxicity)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN: <b>Alternative option 1:</b> Introducing an optional resolution step before HTA committee consideration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN: <b>Alternative option 2:</b> Introducing an optional resolution step <b>before</b> HTA committee consideration, with additional post committee resolution	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN: <b>Alternative option 3:</b> Early Price negotiation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN: <b>Alternative option 4:</b> Introducing an optional resolution step <b>after</b> HTA committee consideration but <b>before</b> advice is finalised	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Expanding resolution step to all relevant cost effectiveness submissions	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Development of a disease specific common model (reference case) for disease areas with high active product development	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Decouple the requirement for the TGA Delegate's overview to support PBAC advice	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Case manager	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

### Triaging submissions

Streamlined pathway for cost-minimisation submissions (therapies not claiming a significant improvement in health outcomes or reduction in toxicity)



Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN

**Alternative option 1:** Introducing an optional resolution step before HTA committee consideration

Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN

**Alternative option 2:** Introducing an optional resolution step **before** HTA committee consideration, with additional post committee resolution

Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN

**Alternative option 3:** Early Price negotiation

Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN

**Alternative option 4:** Introducing an optional resolution step **after** HTA committee consideration but **before** advice is finalised

Expanding resolution step to all relevant cost effectiveness submissions

Development of a disease specific common model (reference case) for disease areas with high active product development

Decouple the requirement for the TGA Delegate's overview to support PBAC advice

Case manager

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

Section 2.2. of the Options Paper sets out four possible reform options relating to proportionate appraisal pathways to calibrate the level of appraisal required for HTA submissions to take the level of risk (levels of uncertainty and potential fiscal impact) and clinical need that the submission represents into account.

Under the subject “Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN”, there are some options that provide different *alternative* mechanisms to address the issues that relate to them.

To what extent could the below different alternative options (if implemented) address the issues that relate to them?

	To a significant extent	To a moderate extent	To a limited extent	Not at all	Don't know
Alternative option 1: Introducing an optional resolution step before HTA committee consideration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Alternative option 2: Introducing an optional resolution step <b>before</b> HTA committee consideration, with additional post committee resolution	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Alternative option 3: Early Price negotiation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Alternative option 4: Introducing an optional resolution step <b>after</b> HTA committee consideration but <b>before</b> advice is finalised	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

What comments do you have about the relative strengths and weaknesses of these alternative potential reform options?

Which of the proposed reform options do you think offers greatest scope to improve the HTA assessment process?

- Alternative option 1: Introducing an optional resolution step before HTA committee consideration
- Alternative option 2: Introducing an optional resolution step **before** HTA committee consideration, with additional post committee resolution
- Alternative option 3: Early Price negotiation
- Alternative option 4: Introducing an optional resolution step **after** HTA committee consideration but **before** advice is finalised
- None of these

Why did you select that response above?

### 3.1. Determination of the Population, Intervention, Comparator, Outcome

Taking all Options within this section: **3.1. Determination of the Population, Intervention, Comparator, Outcome** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Increased early stakeholder input	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Increased transparency for stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Updated guidance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Increased early stakeholder input

Increased transparency for stakeholders

Updated guidance

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### 3.2. Clinical Evaluation Methods

Taking all Options within this section: **3.2. Clinical Evaluation Methods** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Overarching principles for adopting methods in Australian HTA	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methods for the assessment of nonrandomised and observational evidence	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methods for the assessment of surrogate endpoints	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>



	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Generate a curated list of methodologies that are preferred by decision-makers, in collaboration with evaluation groups and sponsors.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Develop an explicit qualitative value framework	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Therapies that target biomarkers (e.g. tumour agnostic cancer therapies, therapies that target particular gene alterations)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmacogenomic technologies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

### Overarching principles for adopting methods in Australian HTA

### Methods for the assessment of nonrandomised and observational evidence

Methods for the assessment of surrogate endpoints

Generate a curated list of methodologies that are preferred by decision-makers, in collaboration with evaluation groups and sponsors

Develop an explicit qualitative value framework

Therapies that target biomarkers (e.g. tumour agnostic cancer therapies, therapies that target particular gene alterations)

Pharmacogenomic technologies

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### 3.3. Economic evaluation

Taking all Options within this section: **3.3. Economic evaluation** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Selection of the comparator	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Valuing of long-term benefits	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Valuing overall	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Selection of the comparator

Valuing of long-term benefits

Valuing overall

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

#### 4.1. Approaches to funding or purchasing new health technologies

Taking all Options within this section: **4.1. Approaches to funding or purchasing new health technologies** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Recognising competition between new health technologies that deliver similar outcomes: <b>Alternative option 1:</b> In conjunction with options for proportionate assessment of cost-minimisation submissions, <b>require offers</b> of a lower price for health technologies that provide no added benefit	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Recognising competition between new health technologies that deliver similar outcomes: <b>Alternative option 2:</b> In conjunction with options for proportionate assessment of cost-minimisation submissions, <b>incentivise offers</b> of a lower price for health technologies that provide no added benefit	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Investigate further options to address budget impact implications of high-cost/high impact health technologies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pricing offer (PO) and negotiation guidance framework	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Post-listing re-assessment of health technologies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Approaches for managing uncertainty - bridging funding coverage for earlier access to therapies of likely HATV and HUCN	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Approaches for managing uncertainty - revised guidance on the uses of different managed entry tools	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Recognising competition between new health technologies that deliver similar outcomes:

**Alternative option 1:** In conjunction with options for proportionate assessment of cost-minimisation submissions, **require offers** of a lower price for health technologies that provide no added benefit

Recognising competition between new health technologies that deliver similar outcomes:

**Alternative option 2:** In conjunction with options for proportionate assessment of cost-minimisation submissions, **incentivise offers** of a lower price for health technologies that provide no added benefit



Investigate further options to address budget impact implications of high-cost/high impact health technologies

Pricing offer (PO) and negotiation guidance framework

Post-listing re-assessment of health technologies

Approaches for managing uncertainty - bridging funding coverage for earlier access to therapies of likely HATV and HUCN

Approaches for managing uncertainty - revised guidance on the uses of different managed entry tools

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

Under the subject “Recognising competition between new health technologies that deliver similar outcomes”, there are two options that provide different alternative mechanisms to address the issues that relate to them.

To what extent could the below different alternative options (if implemented) address the issues that relate to them?

	To a significant extent	To a moderate extent	To a limited extent	Not at all	Don't know
--	-------------------------	----------------------	---------------------	------------	------------

**Alternative option 1:**

In conjunction with options for proportionate assessment of cost-minimisation submissions, **require offers** of a lower price for health technologies that provide no added benefit

<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

**Alternative option 2:**

In conjunction with options for proportionate assessment of cost-minimisation submissions, **incentivise offers** of a lower price for health technologies that provide no added benefit.

<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

What comments do you have about the relative strengths and weaknesses of these alternative potential reform options?

Which of the proposed reform options do you think offers greatest scope to address the issues identified in consultation to date?

- Alternative option 1:** In conjunction with options for proportionate assessment of cost-minimisation submissions, **require offers** of a lower price for health technologies that provide no added benefit
- Alternative option 2:** In conjunction with options for proportionate assessment of cost-minimisation submissions, **incentivise offers** of a lower price for health technologies that provide no added benefit.
- Neither of these

Why did you select that response above?

#### 4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR)

Taking all Options within this section: **4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR)** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
HTA Fee exemptions for products that address AMR	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
HTA Policy and Guidance changes for products that address AMR	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Funding and reimbursement-related changes to support availability of antimicrobials	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

HTA Fee exemptions for products that address AMR

## HTA Policy and Guidance changes for products that address AMR

## Funding and reimbursement-related changes to support availability of antimicrobials

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### 4.3. Understanding the performance of health technologies in practice

Taking all Options within this section: **4.3. Understanding the performance of health technologies in practice** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Oversight – reforms to optimise access to and use of RWD in HTA	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Develop a strategic approach to increase confidence, awareness, and acceptance of cross-jurisdictional and cross-sectoral RWD access and use in HTA	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Data infrastructure	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Methods development	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Develop Guidance framework	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Collection of utilisation and outcome data for provisionally listed health technologies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Oversight – reforms to optimise access to and use of RWD in HTA

Develop a strategic approach to increase confidence, awareness, and acceptance of cross-jurisdictional and cross-sectoral RWD access and use in HTA

Data infrastructure



Methods development

Develop Guidance framework

Collection of utilisation and outcome data for provisionally listed health technologies

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### 5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS

Taking all Options within this section: **5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Development of a priority list	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Identifying therapies to meet priority list (horizon scanning)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Early assessment and prioritisation of potentially promising therapies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Proactive submission invitation and incentivisation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Early PICO scoping	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Development of a priority list

Identifying therapies to meet priority list (horizon scanning)

Early assessment and prioritisation of potentially promising therapies

Proactive submission invitation and incentivisation

Early PICO scoping

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

## 5.2.

Taking all Options within this section: **5.2. Establishment of horizon scanning programs to address specific informational needs within HTA and the health system** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Horizon scanning for advanced therapies (including high cost, HSTs funded through the NHRA) and other potentially disruptive technologies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Horizon Scanning to meet priority areas (including addressing equity and HUCN)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Horizon Scanning to help operational and capacity planning for HTA and health systems	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Horizon scanning for advanced therapies (including high cost, HSTs funded through the NHRA) and other potentially disruptive technologies

Horizon Scanning to meet priority areas (including addressing equity and HUCN)

Horizon Scanning to help operational and capacity planning for HTA and health systems

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### 5.3. Consideration of environmental impacts in the HTA

Taking all Options within this section: **5.3. Consideration of environmental impacts in the HTA** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Completely address the issue(s)

- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Environmental impact reporting	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answer above you can do so below:

Environmental impact reporting



Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

#### 5.4. Mechanisms for continuous review and improvement

Taking all Options within this section: **5.4. Mechanisms for continuous review and improvement** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?



If you would like to expand on your answer above, you can do so below:

A program of continuous review and improvement for current HTA policies and methods

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### 5.5. Capacity and capability of the HTA system

Taking all Options within this section: **5.5. Capacity and capability of the HTA system** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Improve HTA capacity and workforce in Australia	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on your answer above, you can do so below:

Improve HTA capacity and workforce in Australia

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

## 5.6. Strengthen international partnerships and work-sharing

Taking all Options within this section: **5.6. Strengthen international partnerships and work-sharing** into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

- Completely address the issue(s)
- Mostly address the issue(s)
- Address some but not most of the issue(s)
- Address little or none of the issue(s)
- Don't know

If you would like to expand on your answer above you can do so below:

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)?

	Very negative	Negative	Neutral	Positive	Very positive	Don't know
Harmonisation of HTA evaluations	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Work sharing for individual submissions	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Collaboration with international jurisdictions to deliver sustainable access to health technologies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

If you would like to expand on any of your answers above relating to a specific Option, you can do so in the table below:

Harmonisation of HTA evaluations

Work sharing for individual submissions

Collaboration with international jurisdictions to deliver sustainable access to health technologies

Do you have further comments or concerns to add **specific to this topic** that should be considered? For example, here you can detail any unintended consequences or overlooked considerations if applicable.

### Summary: All options overall

*In summary, considering all the draft reform options together:*

How confident are you that the reform options (if implemented) will make health technology assessments **better overall**?

Very confident

- Somewhat confident
- Not very confident
- Not at all confident
- Don't know

If you would like to expand on your answer above you can do so below:

If you wish to submit any additional feedback to support your submission, you may upload this as a Word Document or PDF below.

To ensure that all stakeholders' submissions can be reviewed in a timely fashion we kindly request that files uploaded are a maximum of 5 to 10 pages in length.

Finally, do you have any further comments about the draft Options Paper or consultation you would like to make before submitting your feedback?

Thank you for taking the time to provide feedback. Your participation in this survey will help the HTA Review Reference Committee understand potential implications and identify unintended outcomes of the potential options for reform. Please select the next arrow to complete your online submission and submit your answers.

You will be redirected to the HTA Review Options Paper landing page, and can then close your browser.

© Bastion Insights 2023 | [Privacy Policy](#)

Powered by Qualtrics



